ExcellGene Promotes Dr. Divor Kiseljak to Chief Operations Officer to Drive Recombinant Protein Design, Expression, and Manufacturing
May 19th, 2022
Monthey, Switzerland -PRESS RELEASE- ExcellGene SA, a private-company offering services of research, development, and manufacturing for the biopharmaceutical industry for 20 years, announced today the promotion of Dr. Divor Kiseljak to Chief Operations Officer (COO). Dr. Kiseljak joined the Company in 2012 as a Process Scientist to further ExcellGene’s expertise in transient gene expression, which was part of his doctoral work.
He has most recently held the role of Director of Process Science at ExcellGene and has directly interacted and coordinated with the Company’s clients in academia and industry on diverse projects, ranging from recombinant protein design to gene expression and protein product delivery.
Dr. Kiseljak was the scientific leader for ExcellGene’s Ebola virus vaccine project. The rapid conversion of different Ebola GP1,2 constructs into purified protein was largely based on his work. More recently, he contributed towards elucidating how the SARS-CoV-2 spike protein may be influential in an immunological context¹, and towards the production of high-quality SARS-CoV-2 spike protein expressed from bioreactor-grown CHO cells².
“I am grateful,” Dr. Kiseljak says, “not only on a personal level, but also for what it means to the many new ventures and projects we have recently initiated at ExcellGene. The future is bright with many surprises ahead!”
More about Dr. Kiseljak and his current activities can be viewed on his LinkedIn profile.
- Tumpara, S.; Gründing, A.R.; Sivaraman, K.; Wrenger, S.; Olejnicka, B.; Welte, T.; Wurm, M.J.; Pino, P.; Kiseljak, D.; Wurm, F.M.; Janciauskiene, S. Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α-1 Antitrypsin. Int. J. Mol. Sci. 2021, 22, 7941. https://doi.org/10.3390/ijms22157941
- Pino, P.; Kint, J.; Kiseljak, D.; Agnolon, V.; Corradin, G.; Kajava, A.V.; Rovero, P.; Dijkman, R.; den Hartog, G.; McLellan, J.S.; Byrne, P.O.; Wurm, M.J.; Wurm, F.M. Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes 2020, 8, 1539. https://doi.org/10.3390/pr8121539
About ExcellGene SA
ExcellGene SA, a privately-owned company, offers high quality research, development, and manufacturing services in three key areas: recombinant therapeutics, vaccines, and diagnostics. The Company, spun off from the Swiss Federal Institute of Technology in Lausanne (EPFL), recently celebrated 20 years of helping academic and industry partners. ExcellGene focuses on manufacturing sciences offering services that include difficult to manufacture protein therapeutics and the development of gene therapy products (AAV). Host cells to generate these incorporate CHOExpress® and HEKExpress® systems, which have delivered products for clinical use from bioreactors at scales of 100 to 2500 Liter. The Company has pioneered many innovations utilizing recombinant animal cells in bioreactors and has shared insights and know-how through numerous scientific publications. Recently, with SARS-CoV-2, ExcellGene has delivered milligram to gram quantities of CHO-produced spike protein preparations of the Wuhan, Alpha, Beta, Delta, and Omicron variants. Visit www.excellgene.com to learn more.
For more information on this press release, contact email@example.com or call +41 244719660.
Download the PDF